Genmab — Juni 2019
-
Måske er FDA i gang med en større cost/benefit analyse.
-
altså vi når i mål med 15% stigning per kvartal
-
- maj udtaler FDA: The Real-Time Oncology Review Program is a pilot program and we are continuing to evaluate drug applications on a case by case basis" https://www.raps.org/news-and-articles/news-articles/2019/5/fda-approves-first-nda-under-real-time-oncology-re
-
Lidt ADC stuff - interessant for Zymeworks folk: Analysts say DS-8201 could triple the number of patients who get powerful targeted treatment for breast cancer, the most common tumor in women that kills more than half a million annually. As importantly, its ability to target cancer cells without affecting normal cells is a key advantage over the take-no-prisoners approach of chemotherapy.
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind